Search results

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:348803 CAPLUS Full-text
DN 138:354008
TI Synthesis of diazabicycloalkanecarboxamides as caspase inhibitors
IN Robidoux, Andrea L. C.; Wilson, Jeffrey Douglas; Dieterich, Petra; Storer, Neil; Leonardi, Stefania
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 14 pp., Cont.-in-part of U.S. 6,201,118.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6559304	B1	20030506	US 2000-688301	20001013
	US 6201118	B1	20010313	US 1998-136339	19980819
PRAI	US 1998-136339	A2	19980819		

OS CASREACT 138:354008; MARPAT 138:354008
GI



I



II

AB Diazabicycloalkanecarboxamides I [m = 0-2; n = 0, 1; X = CH, N; R = H, aryl, acyl, (un)substituted alkyl, CO2H, SO2H, CONH2, SO2NH2; R1 = OH, CF3, COCO2H, CO2H, (un)substituted alkyl; R2 = CN, (un)substituted CH:CH2, CH:NOH, alkyl, acyl, COCONH2] were prepared as known caspase inhibitors. Thus, the pyridazodiazepinecarboxamide II was prepared from Br(CH2)4CO2H in 9 steps.

IT **192756-07-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of diazabicycloalkanecarboxamides as caspase inhibitors)

RN 192756-07-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:816645 CAPLUS Full-text
DN 135:344728
TI Asymmetric synthesis of piperazic acid and derivatives
IN Robidoux, Andrea; Serafini, Siro; Dieterich, Petra; Leonardi, Stephania; Stibbard, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083458	A2	20011108	WO 2001-US13330	20010425
	WO 2001083458	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1280780	A2	20030205	EP 2001-930747	20010425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003176691	A1	20030918	US 2002-168463	20020614
	US 6632942	B2	20031014		
PRAI	US 2000-202104P	P	20000504		
	WO 2001-US13330	W	20010425		

OS CASREACT 135:344728; MARPAT 135:344728
GI



I

AB Piperazic acids I [R is H or a carboxy-protecting group; R1, R2 = H or anamino protecting group; R1 and R2 may be taken together to form a fused bicyclic or tricyclicamino protecting group (R1 = R2 ≠ H)] were prepared by treating R4O(CH2)3CH(OR4)CO2R (OR4 is a leaving group) with hydrazines R1NHNHR2 in the presence of a base and an organic solvent. Thus, treating a solution of CbzNHNHCbz (Cbz = PhCH2O2C) and (R)-tert-Bu 2,5-dimesylvalerate in DMF with Na2SO4 and TBAF and stirring the mixture at room temperature for 24 h afforded (S)-tert-Bu 1,2-bis(benzyloxycarbonyl)hexahyd ro-3-pyridazinecarboxylate.

IT **192756-07-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of piperazic acid and derivs.)
RN 192756-07-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:489403 CAPLUS Full-text
DN 135:92659
TI Preparation of carboxamide diazepin derivatives and their inhibition of cathepsin K, cathepsin B, and papain
IN Bhatnagar, Neerja; Mauger, Jacques
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 231 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047930	A1	20010705	WO 2000-FR3622	20001221
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2802927	A1	20010629	FR 1999-16567	19991228
	FR 2802927	B1	20020301		
	EP 1246824	A1	20021009	EP 2000-990087	20001221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016845	A	20021015	BR 2000-16845	20001221
	JP 2003519152	T2	20030617	JP 2001-549400	20001221
	EE 200200362	A	20030815	EE 2002-362	20001221
	NO 2002003107	A	20020827	NO 2002-3107	20020627
	US 2003100550	A1	20030529	US 2002-168116	20020708
PRAI	FR 1999-16567	A	19991228		
	WO 2000-FR3622	W	20001221		

OS MARPAT 135:92659
GI



I

AB The title compds. I [R1 = C(O), R5, SO2R5, C(O)NR6R5; R2 and R7 are such that either R7 represents a hydrogen atom and R2 is such that the group (a) represents the radical of a natural or nonnatural amino acid, or R2 and R7 form together a cycle with the nitrogen and carbon atom whereto they are bound; R3 = CH:N2 or CH2LR4, R4 represents in particular a linear or branched alkyl radical], inhibitors of cathepsin K, cathepsin B, and papain, were prepared E.g., 3-[9(S)-benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-6H-pyridazino[1,2-a][1,2]diazepine-1(S)-carboxamide]-5-methyl-1-benzoyloxyhexane-2-one was prepared

IT **348102-54-5P 348102-56-7P 348102-58-9P**
348102-60-3P 348102-62-5P 348102-64-7P
348102-66-9P 348102-68-1P 348102-70-5P
348102-72-7P 348102-74-9P 348102-94-3P

348102-96-5P 348102-98-7P 348103-00-4P
348103-02-6P 348103-04-8P 348103-06-0P
348103-08-2P 348103-10-6P 348103-12-8P
348103-14-0P 348103-16-2P 348103-18-4P
348103-20-8P 348103-22-0P 348103-24-2P
348103-26-4P 348103-28-6P 348103-30-0P
348103-32-2P 348103-34-4P 348103-36-6P
348103-38-8P 348103-40-2P 348103-42-4P
348103-44-6P 348103-46-8P 348103-48-0P
348103-50-4P 348103-52-6P 348103-54-8P
348103-56-0P 348103-58-2P 348103-59-3P
348103-61-7P 348103-63-9P 348103-65-1P
348103-67-3P 348103-69-5P 348103-71-9P
348103-76-4P 348103-78-6P 348103-80-0P
348103-82-2P 348103-84-4P 348103-86-6P
348103-88-8P 348103-90-2P 348103-92-4P
348103-94-6P 348103-96-8P 348103-98-0P
348104-01-8P 348104-03-0P 348104-05-2P
348104-07-4P 348104-09-6P 348104-11-0P
348104-13-2P 348104-15-4P 348104-17-6P
348104-19-8P 348104-21-2P 348104-23-4P
348104-25-6P 348104-27-8P 348104-29-0P
348104-32-5P 348104-34-7P 348104-36-9P
348104-38-1P 348104-40-5P 348104-42-7P
348104-45-0P 348104-47-2P 348104-49-4P
348104-51-8P 348104-53-0P 348104-55-2P
348104-57-4P 348104-59-6P 348104-61-0P
348104-63-2P 348104-64-3P 348104-65-4P
348104-66-5P 348104-68-7P 348104-70-1P
348104-72-3P 348104-74-5P 348104-76-7P
348104-78-9P 348104-80-3P 348104-82-5P
348104-84-7P 348104-86-9P 348104-88-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxamide diazepin derivs. and their inhibition of cathepsin K, cathepsin B, and papain)

RN 348102-54-5 CAPLUS

CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-56-7 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-,
2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-58-9 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-,
2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-60-3 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-62-5 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-diazo-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-64-7 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-66-9 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-68-1 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-,
2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-70-5 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-72-7 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-74-9 CAPLUS
CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-94-3 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-96-5 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-98-7 CAPLUS
CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-
[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-
1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-00-4 CAPLUS
CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-02-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-04-8 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-06-0 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-08-2 CAPLUS
CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-10-6 CAPLUS
CN 1-Piperazinehexanoic acid, 4-[2-(diethylamino)ethyl]-γ-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-12-8 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-14-0 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-16-2 CAPLUS
CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-18-4 CAPLUS
CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-20-8 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-22-0 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-24-2 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-26-4 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-28-6 CAPLUS

CN 1-Piperazinehexanoic acid, 4-[2-(diethylamino)ethyl]-γ-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-30-0 CAPLUS
CN Hexanoic acid, 6-[(4-methoxyphenyl)thio]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-32-2 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-(2-pyrimidinylthio)-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-34-4 CAPLUS
CN Benzoic acid, 3-(1-cyanoethyl)-, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-36-6 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-38-8 CAPLUS
CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-40-2 CAPLUS

CN 1-Piperidinehexanoic acid, 3-[(diethylamino)carbonyl]-γ-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-42-4 CAPLUS

CN Hexanoic acid, 6-(4-fluorophenoxy)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-44-6 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-46-8 CAPLUS
CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-48-0 CAPLUS
CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-50-4 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-52-6 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 348103-54-8 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-[[(4-methoxyphenyl)methyl]thio]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-56-0 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-58-2 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-59-3 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 348103-61-7 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-63-9 CAPLUS
CN Pentanedioic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-65-1 CAPLUS
CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-67-3 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-69-5 CAPLUS

CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-71-9 CAPLUS
CN Hexanoic acid, 6-[(4-methoxyphenyl)thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-
9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-
a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 348103-76-4 CAPLUS
CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-
(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-
a][1,2]diazepin-
1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 348103-78-6 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-80-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-82-2 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-84-4 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-86-6 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-88-8 CAPLUS
CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-90-2 CAPLUS
CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-92-4 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-94-6 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-96-8 CAPLUS
CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-
[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 348103-98-0 CAPLUS
CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-01-8 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-03-0 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-05-2 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-07-4 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 348104-09-6 CAPLUS
CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-11-0 CAPLUS
CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 348104-13-2 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-15-4 CAPLUS

CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-17-6 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-19-8 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-21-2 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-[[(4-methoxyphenyl)methyl]thio]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-23-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-25-6 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-27-8 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-29-0 CAPLUS
CN Pentanedioic acid, (3S)-3-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-32-5 CAPLUS

CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-34-7 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-9-[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-36-9 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-38-1 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-40-5 CAPLUS
CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-42-7 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-45-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-47-2 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-49-4 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-51-8 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-53-0 CAPLUS
CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-55-2 CAPLUS
CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-57-4 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl
ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-59-6 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-6,10-dioxo-
9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 348104-61-0 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-63-2 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-64-3 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-65-4 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-66-5 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-
(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 348104-68-7 CAPLUS
CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[[2-
(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-,
2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-70-1 CAPLUS
CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-
1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-72-3 CAPLUS
CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-74-5 CAPLUS
CN Hexanoic acid, 6-[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-76-7 CAPLUS
CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 348104-78-9 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-80-3 CAPLUS
CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-82-5 CAPLUS
CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-84-7 CAPLUS
CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-86-9 CAPLUS
CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-88-1 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:144862 CAPLUS Full-text
DN 132:180588
TI Preparation of (annelated)piperazic acids as caspase inhibitor intermediates
IN Robidoux, Andrea L. C.; Wilson, Jeffrey Douglas; Dieterich, Petra; Storer, Neil; Leonardi, Stefania
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010979	A1	20000302	WO 1999-US19080	19990819
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6201118	B1	20010313	US 1998-136339	19980819
	US 6177565	B1	20010123	US 1999-235894	19990122
	AU 9956840	A1	20000314	AU 1999-56840	19990819
	EP 1104409	A1	20010606	EP 1999-943814	19990819
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001031862	A1	20011018	US 2001-789049	20010220
PRAI	US 1998-136339	A	19980819		
	US 1999-235894	A	19990122		
	WO 1999-US19080	W	19990819		

OS CASREACT 132:180588; MARPAT 132:180588
GI



I

AB Title compds., e.g., I (R2 = H, alkyl, aryl, etc.; Z = bond or CH2)[II; R = H, R1 = Z1CO2H, Z1 = (un)substituted (oxo)alkylene] were prepared and cyclized to II (RR1 = COZ1). Thus, Br(CH2)3CHBrCO2CMe3 (preparation given) was cyclocondensed with (PhCH2O2CNH)2 to give I (R2 = CMe3, Z = CH2)(II; R = R1 = CO2CH2Ph) which was deprotected and the product N-acylated with (S)-3-phthalimido-2,6-dioxopyran to give II [R = H, R1 = (S)-HO2CCHR3CH2CH2CO, R3 = phthalimido]. The latter was treated with

SOCl2/2,6-lutidine to give, after hydrazinolysis, II [RR1 = (S)-COCHNH2CH2CH2CO].

IT **192756-07-3P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of (annelated)piperazic acids as caspase inhibitor intermediates)

RN 192756-07-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:386128 CAPLUS Full-text
DN 131:144580
TI An efficient stereoselective synthesis of [3S(1S,9S)]-3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor
AU Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(11), 1587-1592
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB The title compound (I) is a potent interleukin-1β-converting enzyme inhibitor. Recently, an efficient chiral synthesis of I was accomplished in our labs. The overall yield of this 18-step stereoselective synthesis was 9.8%.
IT **192755-43-4P 234752-71-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(stereoselective preparation of interleukin converting enzyme inhibitor)
RN 192755-43-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234752-71-7 CAPLUS
CN Butanoic acid, 3-[[[(1S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-23-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of interleukin converting enzyme inhibitor)
RN 174799-23-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:136764 CAPLUS Full-text
DN 130:196957
TI Preparation of bicyclic peptide derivatives as interleukin-1β converting enzyme inhibitors
IN Batchelor, Mark James; Bebbington, David; Bemis, Guy W.; Fridman, Wolf Herman; Gillespie, Roger John; Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Matharu, Saroop Singh; Mullican, Michael D.; Murcko, Mark A.; Murdoch, Robert; Zelle, Robert E.
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 189 pp., Cont.-in-part of U.S. Ser. No. 575,641.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874424	A	19990223	US 1996-598332	19960208
	US 6008217	A	19991228	US 1995-575641	19951220
	US 6204261	B1	20010320	US 1996-761483	19961206
	IN 182290	A	19990306	IN 1996-CA2188	19961218
	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9610798	A	19970707	ZA 1996-10798	19961220
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9612258	A	19990713	BR 1996-12258	19961220
	CN 1229412	A	19990922	CN 1996-199828	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	JP 2003137896	A2	20030514	JP 2002-306094	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	US 6258948	B1	20010710	US 1999-400639	19990921
	US 6423840	B1	20020723	US 2001-773477	20010131
	AU 756253	B2	20030109	AU 2001-76122	20010928
	US 2003225269	A1	20031204	US 2002-58522	20020128
PRAI	US 1995-575641	A2	19951220		
	US 1996-598332	A2	19960208		
	US 1996-712878	A2	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	JP 1997-523098	A3	19961220		
	WO 1996-US20843	W	19961220		
	US 1999-400639	A3	19990921		

US 2001-773477 A3 20010131

OS MARPAT 130:196957

GI



I



II

AB Title compds. I [m = 1-2; R3 = CN, CHO, COCH2-T1-R11, COCH2F, C:NOR9, COAr2; R5 = COR10, CO2R9, CONR102, SO2R9, SO2NHR10, COCH2OR9, COCOR10, R9, H, COCO2R10, COCONR9R10; Y = O, H2; T1 = O, S, S(O), SO2; R9 = Ar3, (un)branched C1-6 alkyl optionally unsatd. and optionally substituted with Ar3; R10 = H, Ar3, C3-6 cycloalkyl, any group R9; R11 = Ar4, (CH2)1-3Ar4, H, COAr4; R15 = OH, OAr3, NHOH, (un)branched C1-6 alkoxy optionally unsatd. and optionally substituted with Ar3, CONH2, OR5, OH, OR9, CO2H; Ar2 = (un)substituted 2-oxazolyl, 2-benzoxazolyl, 2-thiazolyl, 2-benzothiazolyl; Ar3, Ar4 = optionally substituted, nitrogen-containing heteroarom. or heterocyclic group containing 1-3 rings] were prepared as inhibitors of interleukin-1β converting enzyme. Thus, bicyclic peptide derivative II was prepared and shown to have Ki = 13 nM in a UV-visible assay and IC50 = 11000 nM in a peripheral blood mononuclear cell (PBMC) assay.

IT **174799-23-6P 192754-08-8P 192754-09-9P 192755-43-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of bicyclic peptide derivs. as interleukin-1β converting enzyme inhibitors)

RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192754-08-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[(2,6-dichlorophenyl)methoxy]imino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-09-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192755-43-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-04-3P 174799-05-4P 174799-28-1P**
175209-10-6P 175209-11-7P 175209-35-5P
175209-36-6P 175209-41-3P 175209-48-0P
175209-61-7P 175209-93-5P 192753-95-0P
192753-97-2P 192754-02-2P 192754-03-3P
192754-10-2P 192754-11-3P 192754-50-0P
192754-51-1P 192754-52-2P 192754-53-3P
192754-56-6P 192754-57-7P 192754-59-9P
192754-61-3P 192754-76-0P 192754-98-6P
192755-26-3P 192755-28-5P 192755-29-6P
192755-30-9P 192755-31-0P 192755-32-1P
192755-33-2P 192755-34-3P 192755-99-0P
192756-00-6P 192756-01-7P 192756-02-8P
192756-03-9P 192756-04-0P 192756-05-1P
192756-06-2P 192756-07-3P 192756-08-4P
192756-09-5P 192756-10-8P 192756-11-9P
192756-12-0P 192756-13-1P 192756-14-2P
192756-15-3P 192756-16-4P 192756-17-5P
192756-19-7P 192756-20-0P 192756-21-1P
192756-22-2P 192756-23-3P 192756-24-4P
192756-25-5P 192756-26-6P 192756-28-8P
192756-29-9P 192756-30-2P 192756-31-3P
192756-32-4P 192756-33-5P 192756-34-6P
192756-35-7P 192756-36-8P 192756-37-9P
192756-38-0P 192756-39-1P 192756-40-4P
192756-41-5P 192756-42-6P 192756-43-7P
192756-44-8P 192756-45-9P 192756-46-0P
192756-48-2P 192756-49-3P 192756-50-6P
192756-51-7P 192756-52-8P 192756-53-9P
192756-54-0P 192756-55-1P 192756-56-2P
192756-57-3P 192756-58-4P 192756-59-5P
192756-61-9P 192756-62-0P 192756-63-1P
192756-65-3P 192756-66-4P 192756-68-6P
192756-69-7P 192756-70-0P 192756-71-1P
192756-73-3P 192756-74-4P 192756-75-5P
192756-76-6P 192756-77-7P 192756-78-8P

192756-79-9P 192756-80-2P 192756-81-3P
192756-82-4P 192756-83-5P 192756-84-6P
192756-86-8P 192756-87-9P 192756-88-0P
192756-89-1P 192762-50-8P 220743-36-2P
220743-37-3P 220743-39-5P 220743-43-1P
220743-44-2P 220743-45-3P 220743-47-5P
220743-50-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic peptide derivs. as interleukin-1β converting enzyme inhibitors)

RN 174799-04-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-05-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 174799-28-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 175209-10-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-
phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-
4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-
phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-
4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-48-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-93-5 CAPLUS
CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-95-0 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192753-97-2 CAPLUS
CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-02-2 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-03-3 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4R)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-10-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[(2,6-dichlorophenyl)methoxy]imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-11-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-50-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-51-1 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-52-2 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-53-3 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-56-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-57-7 CAPLUS

CN 2-Benzoxazolebutanoic acid, β-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-59-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[(2-chlorophenyl)methyl]thio]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-61-3 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-76-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-98-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,8S,9S)-9-(benzoylamino)octahydro-8-methyl-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-26-3 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-28-5 CAPLUS
CN Sulfonium, [(3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl][(2-chlorophenyl)methyl]methyl-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 192755-27-4
CMF C30 H34 Cl N4 O7 S

Absolute stereochemistry.



CM 2

CRN 14874-70-5
CMF B F4
CCI CCS



RN 192755-29-6 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-30-9 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-31-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-32-1 CAPLUS
CN Benzoic acid, 2,6-dimethyl-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-33-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-34-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-chloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-99-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-00-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-01-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-02-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylcarbonyl)amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-03-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-naphthalenylcarbonyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-04-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[([1,1'-biphenyl]-4-
ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-
1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-05-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-thienylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-06-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(2-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-07-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-08-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclopropylcarbonyl)amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-09-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1,3-benzodioxol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-10-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-chlorobenzoyl)amino]octahydro-6,10-

dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-11-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3,4,5-
trimethoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-12-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylamino)benzoyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-13-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-14-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(methylamino)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-15-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(ethylsulfonyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-16-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-17-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(2,4-dimethyl-5-thiazolyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-19-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(6-hydroxy-2-naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-20-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclohexylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-21-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylsulfonyl)amino]-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-22-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(dimethylamino)sulfonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-23-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-aminooctahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-24-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[2-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-25-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-aminobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-26-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzotriazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-28-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzimidazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-29-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-30-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-31-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(4-methoxy-2-quinolinyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-32-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(6-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-33-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(8-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-34-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(3-amino-2-naphthalenyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-35-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[[4-(dimethylamino)-1-naphthalenyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-36-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(thieno[2,3-b]thien-2-
ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-
oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-37-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-phenoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-38-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2,6-dichlorobenzoyl)amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-39-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-imidazol-2-ylcarbonyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-40-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1,2,3-thiadiazol-5-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-
oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-41-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methylsulfonyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-42-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylmethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-43-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-44-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-45-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-46-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-48-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-49-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-50-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-hydroxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-51-7 CAPLUS
CN Benzoic acid, 4-hydroxy-, 4-[[[(4S,7S)-4-[[[(1S)-2-carboxy-1-formylethyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-52-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-difluorobenzoyl)amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-53-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-fluorobenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-54-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(methylsulfonyl)benzoyl]amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-55-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-56-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-57-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-dichlorobenzoyl)amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-58-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-2-methylbenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-59-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(5-chloro-2-methylbenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-61-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-62-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(dimethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-63-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-

(dimethylamino)benzoyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-65-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(6-methyl-1,3-benzodioxol-5-yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-66-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-acetylbenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-68-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-hydroxy-2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-69-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-hydroxy-3-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-70-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-

(aminosulfonyl)benzoyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-71-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-
(hydroxymethyl)benzoyl]amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-73-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3-chlorobenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-74-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3,5-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-75-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-76-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-77-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxopropyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-78-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(phenylacetyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-79-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(3-methyl-1-oxobutyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-80-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxobutyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-81-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[[(methylamino)carbonyl]amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-82-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methoxycarbonyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-83-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoyloxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-84-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluoro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-86-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-87-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-88-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-hydroxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-89-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-(phenylmethoxy)benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192762-50-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(oxophenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-36-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-37-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(1-methyl-1H-indol-3-yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-39-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(benzo[b]thien-3-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-43-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-benzofuranylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-44-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(2E)-1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 220743-45-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-indol-3-ylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-47-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[3,4-bis(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220743-50-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **175211-62-8P 192753-72-3P 192753-74-5P**
192753-76-7P 192753-79-0P 192753-85-8P
192753-87-0P 192753-91-6P 192753-92-7P
192753-94-9P 192753-96-1P 192754-00-0P
192754-01-1P 220744-52-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic peptide derivs. as interleukin-1β converting enzyme inhibitors)

RN 175211-62-8 CAPLUS
CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-72-3 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-74-5 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-76-7 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-79-0 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-85-8 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-87-0 CAPLUS

CN 2-Benzoxazolebutanoic acid, β-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-91-6 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[(2-chlorophenyl)methyl]thio]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-92-7 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-94-9 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192753-96-1 CAPLUS
CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-00-0 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-01-1 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220744-52-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:788773 CAPLUS Full-text
DN 130:66805
TI Preparation of peptide inhibitors of interleukin-1β converting enzyme
IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.
PA Vertex Pharmaceuticals, Incorporated, USA
SO U.S., 106 pp., Cont.-in-part of U.S. 5,656,627.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847135	A	19981208	US 1995-440898	19950525
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6103711	A	20000815	US 1995-465216	19950605
	TW 509698	B	20021111	TW 1995-84105903	19950609
	IN 181338	A	19980516	IN 1995-CA659	19950612
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1159196	A	19970910	CN 1995-194381	19950616
	BR 9508051	A	19971021	BR 1995-8051	19950616
	HU 76622	A2	19971028	HU 1996-3475	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	EP 1394175	A1	20040303	EP 2003-22215	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 5973111	A	19991026	US 1997-828941	19970328
	IN 183119	A	19990911	IN 1997-CA778	19970430
	US 6420522	B1	20020716	US 1999-430822	19991029
	US 2002099042	A1	20020725	US 2001-886773	20010621
PRAI	US 1994-261452	A2	19940617		
	US 1995-405581	A2	19950317		
	US 1995-440898	A3	19950525		
	US 1995-465216	A3	19950605		
	IN 1995-CA659	A1	19950612		

EP 1995-925257 A3 19950616
WO 1995-US7617 W 19950616
US 1999-430822 A3 19991029

OS MARPAT 130:66805

AB Interleukin-1β converting enzyme inhibitors R1NHX1[(CH2)mT](CH2)gR3 (X1 = CH, N; g = 0, 1; m = 0-2; T = a cyclic group, OH, CF3, COCO2H, CO2H; R1 = R4ZNR5CR6R7CO or substituted derivs., where R4 represents certain ring systems; R5 = H, a cyclic group, alkyl, arylcarbonyl, arylsulfonyl, etc.; CR6R7 form a saturated carbocyclic or heterocyclic ring; R3 = CN, 1-alkenyl, alkoxyiminomethyl) were prepared Thus, N-(N-acetyltyrosinylvalinylpipecolyl)-3-amino-4-oxobutanoic acid was prepared and showed IC50 = 6-11 μM for inhibition of interleukin-1β converting enzyme.

IT **175209-10-6P 175209-11-7P 175209-35-5P**
175209-36-6P 175209-41-3P 175209-44-6P
175209-48-0P 175209-61-7P 175209-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of peptide inhibitors of interleukin-1β converting enzyme)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-44-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)(CA INDEX NAME)

Absolute stereochemistry.



RN 175209-48-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **175211-62-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of peptide inhibitors of interleukin-1β converting enzyme)
RN 175211-62-8 CAPLUS
CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:541852 CAPLUS Full-text
DN 127:234612
TI Preparation of heterocyclyl aspartaldehyde peptide derivatives as interleukin-1β converting enzyme inhibitors
IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.
PA Vertex Pharmaceuticals, Inc., USA
SO U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 261,452.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5656627	A	19970812	US 1995-405581	19950317
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5847135	A	19981208	US 1995-440898	19950525
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6025147	A	20000215	US 1995-460973	19950605
	TW 509698	B	20021111	TW 1995-84105903	19950609
	IN 181338	A	19980516	IN 1995-CA659	19950612
	ZA 9504988	A	19961217	ZA 1995-4988	19950615
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1159196	A	19970910	CN 1995-194381	19950616
	BR 9508051	A	19971021	BR 1995-8051	19950616
	HU 76622	A2	19971028	HU 1996-3475	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	EP 1394175	A1	20040303	EP 2003-22215	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 5973111	A	19991026	US 1997-828941	19970328
	IN 183119	A	19990911	IN 1997-CA778	19970430
	US 6420522	B1	20020716	US 1999-430822	19991029
	US 2002099042	A1	20020725	US 2001-886773	20010621
PRAI	US 1994-261452	A2	19940617		
	US 1995-405581	A2	19950317		
	US 1995-440898	A3	19950525		

	US 1995-465216	A3	19950605
	IN 1995-CA659	A1	19950612
	EP 1995-925257	A3	19950616
	WO 1995-US7617	W	19950616
	US 1999-430822	A3	19991029

OS MARPAT 127:234612

GI



I



II



III

AB The present invention relates to novel classes of compds. I [X1 = CH, N; q = 0, 1; J = independently H, OH, F; m = 0-2; T = Ar3, OH, CF3, COCO2H, CO2H, COCH2OH, CONHOH, SO2NHR, SO3H, P(O)(OH)NH2, CONHCN, OSO3H, CONHSO2R16, PO3H2, P(O)(OH)OR16, P(O)(OH)R16, OPO3H2, OP(O)(OH)OR16, OP(O)(OH)R16, NHPO3H2, NHP(O)(OH)OR16, NHP(O)(OH)R16, COCH:C(OH)CO2H, 5- or 6-membered heterocyclic ring; R16 = C1-6 alkyl; R1 = optionally substituted fragment Q; X2 = O, CH2, NH, S, S(O), SO2; X5 = CH, N; n = 0-1, d = 0-2, such that n + d + d = 2; R3 = CN, CH:CHR9, CH:NOR9, (CH2)1-3T1R9, CJ2R9, COR13, COCONR5R10; each R4 = H, Ar1, R9, T1R9, (CH2)1-3T1R9; each T1 = CH:CH, O, S, S(O), SO2, NR10, NR10CO, CO, O2C, CO2, CONR10, O2CNR10, NR10CONR10, SO2NR10, NR10SO2, NR10SO2NR10; R5 = H, Ar1, COAr1, SO2Ar1, R9, CONR9, CO2R9, SO2R9, CONAr1R10, SO2NAr1R10, CONR9R10, SO2NR9R10; R5 = Ar1, SO2Ar1, COR9, CONAr1R10, SO2NAr1R10, CONR9R10, SO2NR9R10; R9 = optionally substituted, straight or branched C1-6 alkyl; R10 = H, C1-6 straight or branched alkyl; R13 = H, Ar1, Ar2, R9, T1R9, (CH2)1-3T1R9; Ar1 = aryl, cycloalkyl, or heterocyclyl group containing 1-3 rings and 3-15 ring atoms; Ar2 = optionally benzo-fused 5-membered heterocyclyl; Ar3 = optionally substituted Ph or 5-membered heterocyclic ring] which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochem. features. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compds. and compns. of this invention. Thus,

cyclocondensation of Et 2-aminopyrrolidine-5- carboxylate with 4-ethoxymethylene-2-phenyl-2-oxazolidin-2-one gave 32% pyrrolopyrimidine II. Saponification of II, followed by coupling with tert-Bu (3S)-amino-4-oxobutanoate semicarbazone, diastereomer separation, and deprotection, gave ICE inhibitors III. III and related compds. inhibited ICE with Ki = 0.011 to 35 μM in a UV-visible assay and IC50 = 0.50 to >35 μM in a cell assay.

IT **175209-10-6P 175209-11-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl aspartaldehyde peptide derivs. as interleukin-1β converting enzyme inhibitors)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



Appl's

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:502830 CAPLUS Full-text
DN 127:122000
TI Inhibitors of interleukin-1β converting enzyme
IN Batchelor, Mark J.; Bebbington, David; Bemis, Guy W.; Fridman, Wolf Herman; Gillespie, Roger J.; Golec, Julian M. C.; Gu, Yong; Lauffer, David J.; Livingston, David J.; Matharu, Saroop S.; Mullican, Michael D.; Murcko, Mark A.; Murdoch, Robert; Nyce, Philip L.; Robidoux, Andrea L. C.; et al.
PA USA
SO PCT Int. Appl., 946 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6008217	A	19991228	US 1995-575641	19951220
	US 5874424	A	19990223	US 1996-598332	19960208
	US 5985863	A	19991116	US 1996-712878	19960912
	US 6204261	B1	20010320	US 1996-761483	19961206
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9612258	A	19990713	BR 1996-12258	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	AU 756253	B2	20030109	AU 2001-76122	20010928
PRAI	US 1995-575641	A	19951220		
	US 1996-598332	A	19960208		
	US 1996-712878	A	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	WO 1996-US20843	W	19961220		

OS MARPAT 127:122000
AB Compds. R(CH2)nCH(NHR1)(CR22)mR3 [R = NC, R4CH:CH, R4ON:CH, R4CR22, etc. where R2 is independently selected from H, OH, F and R4 is (un)substituted alkyl; R1 = R5NHCHR6CONR7CHR8CO, where CHR6CONR7 is a 2-oxoazepine ring substituted by benzo, pyrido, thieno, or related rings at the 6,7-position and optionally may have O, NH, S, SO, or SO2 at the 5-position, R5 and R8 are H, cyclic group, etc.; R3 = OH, COCOCO2H, CO2H, or any bioisosteric replacement for CO2H; m = 0, 1, 2; n = 0, 1]

were prepared as inhibitors of interleukin-1β converting enzyme. Thus, [1S,9S(2RS,3S)]-9- benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-N-(2-benzyloxy-5- oxotetrahydrofuran-3-yl)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide was prepared and shown to have IC50 values of 900 and 600 nM, resp., in the peripheral blood mononuclear cell (PBMC) and whole human blood assays.

IT **192754-50-0P 192755-43-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitors of interleukin-1β converting enzyme)

RN 192754-50-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192755-43-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-05-4P 174799-23-6P 175209-10-6P 175209-11-7P 175209-35-5P 175209-36-6P 175209-41-3P 175209-44-6P 175209-48-0P 175209-61-7P 192753-76-7P 192754-51-1P**

192754-52-2P 192754-53-3P 192754-54-4P
192754-56-6P 192754-57-7P 192754-59-9P
192754-61-3P 192754-76-0P 192754-98-6P
192755-26-3P 192755-28-5P 192755-30-9P
192755-31-0P 192755-32-1P 192755-33-2P
192755-40-1P 192755-94-5P 192755-95-6P
192755-99-0P 192756-00-6P 192756-01-7P
192756-02-8P 192756-03-9P 192756-04-0P
192756-07-3P 192756-10-8P 192756-12-0P
192756-28-8P 192756-32-4P 192756-36-8P
192756-44-8P 192756-46-0P 192756-50-6P
192756-63-1P 192756-67-5P 192756-73-3P
192756-78-8P 192756-79-9P 192756-90-4P
192756-91-5P 192759-92-5P 192759-98-1P
192762-50-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of interleukin-1β converting enzyme)

RN 174799-05-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 174799-23-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-10-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS
CN 2-Benzoxazolebutanoic acid, 7-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-44-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 175209-48-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192753-76-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-51-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-52-2 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-53-3 CAPLUS
CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-54-4 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192754-56-6 CAPLUS
CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-57-7 CAPLUS

CN 2-Benzoxazolebutanoic acid, β-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-59-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[(2-chlorophenyl)methyl]thio]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-61-3 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-76-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-98-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,8S,9S)-9-(benzoylamino)octahydro-8-methyl-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-26-3 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-
tetrazol-5-yl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-28-5 CAPLUS
CN Sulfonium, [(3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl][(2-chlorophenyl)methyl]methyl-, tetrafluoroborate(1-) (9CI) (CA
INDEX NAME)

CM 1

CRN 192755-27-4
CMF C30 H34 Cl N4 O7 S

Absolute stereochemistry.



CM 2

CRN 14874-70-5
CMF B F4
CCI CCS



RN 192755-30-9 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-31-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-32-1 CAPLUS
CN Benzoic acid, 2,6-dimethyl-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-33-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-40-1 CAPLUS
CN Butanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, ethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-94-5 CAPLUS
CN Butanoic acid, 3-[[[9-[[4-(acetylamino)-3-chlorobenzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-95-6 CAPLUS
CN Butanoic acid, 3-[[[9-[(3,5-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-99-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-00-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-01-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-chlorobenzoyl)amino]octahydro-6,10-

dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-02-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylcarbonyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-03-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-naphthalenylcarbonyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-04-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[([1,1'-biphenyl]-4-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-07-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-10-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-chlorobenzoyl)amino]octahydro-6,10-

dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-12-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylamino)benzoyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-28-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzimidazol-5-
ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-
1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-32-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(6-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-36-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(thieno[2,3-b]thien-2-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-44-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

,

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-46-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-50-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-hydroxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-63-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(dimethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-67-5 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[(1H-indol-2-ylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-73-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-78-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(phenylacetyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-79-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(3-methyl-1-oxobutyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-90-4 CAPLUS
CN Butanoic acid, 3-[[[9-[[[(4-chlorophenyl)amino]oxoacetyl]amino]octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-91-5 CAPLUS
CN Butanoic acid, 3-[[[9-[[(2,6-dimethoxyphenyl)oxoacetyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-92-5 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-
pyridinyloxy)-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-98-1 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192762-50-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(oxophenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-04-3 192759-91-4**
RL: RCT (Reactant); RACT (Reactant or reagent)

(inhibitors of interleukin-1β converting enzyme)

RN 174799-04-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-91-4 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-bromo-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **175211-62-8P 192753-72-3P 192753-74-5P**
192753-79-0P 192753-85-8P 192753-91-6P
192753-92-7P 192753-94-9P 192753-96-1P
192754-00-0P 192754-01-1P 192754-08-8P
192754-09-9P 192754-46-4P 192757-33-8P
192757-35-0P 192757-38-3P 192757-41-8P
192757-44-1P 192757-46-3P 192757-47-4P
192757-48-5P 192757-49-6P 192759-71-0P
192759-72-1P 192759-74-3P 192759-75-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(inhibitors of interleukin-1β converting enzyme)

RN 175211-62-8 CAPLUS

CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-

6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-72-3 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-74-5 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-79-0 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-85-8 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-91-6 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[(2-chlorophenyl)methyl]thio]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-92-7 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-94-9 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192753-96-1 CAPLUS
CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-00-0 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-01-1 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-08-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[(2,6-dichlorophenyl)methoxy]imino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-09-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-46-4 CAPLUS
CN Butanoic acid, 3-[[[9-[(3,5-dichloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-33-8 CAPLUS
CN 1-Naphthalenecarboxylic acid, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-35-0 CAPLUS
CN 4-Isoxazolecarboxylic acid, 5-methyl-3-phenyl-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-38-3 CAPLUS
CN Benzoic acid, 2-phenoxy-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-41-8 CAPLUS
CN Benzoic acid, 3-phenoxy-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-44-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-methyl-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-46-3 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-diazo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-47-4 CAPLUS
CN Pentanoic acid, 5-diazo-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-48-5 CAPLUS
CN Pentanoic acid, 5-diazo-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-49-6 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-diazo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-71-0 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-72-1 CAPLUS
CN Benzoic acid, 2,6-dimethyl-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-74-3 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-75-4 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **175209-93-5P 192753-87-0P 192753-95-0P**
192753-97-2P 192754-02-2P 192754-03-3P
192754-10-2P 192754-11-3P 192755-29-6P
192755-34-3P 192756-96-0P 192757-06-5P
192757-24-7P 192757-36-1P 192757-39-4P
192757-42-9P 192757-45-2P 192757-50-9P
192757-51-0P 192759-69-6P 192759-70-9P
192759-73-2P 192759-80-1P 192759-81-2P
192759-82-3P 192759-83-4P 192759-84-5P
192759-85-6P 192759-86-7P 192759-87-8P
192759-88-9P 192759-89-0P 192759-90-3P
192759-93-6P 192759-96-9P 192759-97-0P
192760-00-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(inhibitors of interleukin-1β converting enzyme)

RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-87-0 CAPLUS

CN 2-Benzoxazolebutanoic acid, β-[[[(1S,9S)-9-(benzoylamino)octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192753-95-0 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192753-97-2 CAPLUS
CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-02-2 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-03-3 CAPLUS
CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 192754-10-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[(2,6-dichlorophenyl)methoxy]imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192754-11-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192755-29-6 CAPLUS
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-34-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-chloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-96-0 CAPLUS
CN Butanoic acid, 4-(methoxyimino)-3-[[[octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192757-06-5 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(phenylmethoxy)imino]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192757-24-7 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-36-1 CAPLUS
CN 4-Isoxazolecarboxylic acid, 5-methyl-3-phenyl-, 4-carboxy-3-[[[octahydro-9-
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192757-39-4 CAPLUS
CN Benzoic acid, 2-phenoxy-, 4-carboxy-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-42-9 CAPLUS
CN Benzoic acid, 3-phenoxy-, 4-carboxy-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-45-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-methyl-, 4-carboxy-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-50-9 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-bromo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192757-51-0 CAPLUS
CN Pentanoic acid, 5-bromo-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-69-6 CAPLUS
CN Pentanoic acid, 5-bromo-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-70-9 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-bromo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-73-2 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-thiazolylthio)-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-80-1 CAPLUS

CN 1(6H)-Pyrimidinepentanoic acid, β-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ,6-dioxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-81-2 CAPLUS

CN 1(6H)-Pyrimidinepentanoic acid, β-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ,6-dioxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-82-3 CAPLUS
CN Pentanoic acid, 5-[(3-chloro-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)oxy]-3-
[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-83-4 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-
tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-84-5 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-85-6 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-86-7 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-87-8 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-88-9 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-89-0 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-90-3 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-93-6 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-96-9 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-97-0 CAPLUS
CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192760-00-2 CAPLUS
CN Butanoic acid, 3-[[[9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-28-1P 192756-05-1P 192756-06-2P**
192756-08-4P 192756-09-5P 192756-11-9P
192756-13-1P 192756-14-2P 192756-15-3P
192756-16-4P 192756-17-5P 192756-18-6P
192756-19-7P 192756-20-0P 192756-21-1P
192756-22-2P 192756-23-3P 192756-24-4P
192756-25-5P 192756-26-6P 192756-27-7P
192756-29-9P 192756-30-2P 192756-31-3P
192756-33-5P 192756-34-6P 192756-35-7P
192756-37-9P 192756-38-0P 192756-39-1P
192756-40-4P 192756-41-5P 192756-42-6P
192756-43-7P 192756-45-9P 192756-47-1P
192756-48-2P 192756-49-3P 192756-51-7P
192756-52-8P 192756-53-9P 192756-54-0P
192756-55-1P 192756-56-2P 192756-57-3P
192756-58-4P 192756-59-5P 192756-60-8P
192756-61-9P 192756-62-0P 192756-64-2P
192756-65-3P 192756-66-4P 192756-68-6P
192756-69-7P 192756-70-0P 192756-71-1P
192756-72-2P 192756-74-4P 192756-75-5P
192756-76-6P 192756-77-7P 192756-80-2P
192756-81-3P 192756-82-4P 192756-83-5P
192756-84-6P 192756-85-7P 192756-86-8P
192756-87-9P 192756-88-0P 192756-89-1P
192756-92-6P 192766-55-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)
(inhibitors of interleukin-1β converting enzyme)

RN 174799-28-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-05-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-thienylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-06-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(2-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-08-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclopropylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-09-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1,3-benzodioxol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-11-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3,4,5-

trimethoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-13-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-14-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(methylamino)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-15-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(ethylsulfonyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-16-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-17-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(2,4-dimethyl-5-thiazolyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-18-6 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[[(5-methyl-3-isoxazolyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-19-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(6-hydroxy-2-naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-20-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclohexylcarbonyl)amino]octahydro-6,10-

dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-21-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-
[(phenylsulfonyl)amino]-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-22-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(dimethylamino)sulfonyl]amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-23-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-aminooctahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-24-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[2-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-25-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-aminobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-26-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzotriazol-5-
ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-
1-
yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-27-7 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[[(1-methyl-1H-indol-2-
yl)carbonyl]amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-29-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-30-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-31-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(4-methoxy-2-quinolinyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-33-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(8-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-34-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[(3-amino-2-naphthalenyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-35-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[[4-(dimethylamino)-1-naphthalenyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-37-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-phenoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-38-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2,6-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-39-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-imidazol-2-ylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-40-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1,2,3-thiadiazol-5-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-41-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-

[(methylsulfonyl)amino]benzoyl
]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-
yl]carbonyl]amino]-
4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-42-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-
(acetylmethylamino)benzoyl]amino]octahyd
ro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-
oxo-
, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-43-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(1-hydroxy-2-
naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-
a][1,2]diazepin-
1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-45-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-47-1 CAPLUS
CN Butanoic acid, 3-[[[9-[(benzo[b]thien-2-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-48-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-49-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chlorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-51-7 CAPLUS
CN Benzoic acid, 4-hydroxy-, 4-[[[(4S,7S)-4-[[[(1S)-2-carboxy-1-formylethyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-52-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-difluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-53-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-54-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(methylsulfonyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-55-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-56-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-57-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-dichlorobenzoyl)amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-58-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-2-methylbenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-59-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(5-chloro-2-methylbenzoyl)amino]octahydro-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-60-8 CAPLUS
CN Butanoic acid, 3-[[[9-[(2-benzofuranylcarbonyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-61-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[[4-methyl-2-[4-
(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-6,10-dioxo-6H-
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-62-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-
(dimethylamino)benzoyl]amino]octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-64-2 CAPLUS
CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-
oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192756-65-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[(6-methyl-1,3-benzodioxol-5-yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-66-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-acetylbenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-68-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-hydroxy-2-methylbenzoyl)amino]-
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-69-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-hydroxy-3-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-70-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(aminosulfonyl)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-71-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(hydroxymethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-72-2 CAPLUS
CN Butanoic acid, 3-[[[9-[[3,5-bis(acetylamino)benzoyl]amino]octahydro-6,10-
dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-74-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3,5-dichlorobenzoyl)amino]octahydr
o-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-75-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-
,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-76-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-77-7 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxopropyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-80-2 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxobutyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-81-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[[(methylamino)carbonyl]amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-82-4 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methoxycarbonyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-83-5 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoyloxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-84-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluoro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-85-7 CAPLUS
CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[(1-oxo-3-phenyl-2-propenyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 192756-86-8 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-87-9 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-88-0 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-hydroxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-89-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-(phenylmethoxy)benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-92-6 CAPLUS
CN Butanoic acid, 3-[[[9-[[4-(acetylamino)-3,5-dichlorobenzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192766-55-5 CAPLUS
CN Butanoic acid, 3-[[[9-[[4-(acetyloxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:397284 CAPLUS Full-text
DN 127:44456
TI Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1β-Converting Enzyme Inhibitor
AU Dolle, Roland E.; Prasad, C. V. C.; Prouty, Catherine P.; Salvino, Joseph M.; Awad, Mohamed M. A.; Schmidt, Stanley J.; Hoyer, Denton; Ross, Tina Morgan; Graybill, Todd L.; Speier, Gary J.; Uhl, Joanne; Miller, Robert; Helaszek, Carla T.; Ator, Mark A.
CS Sanofi Winthrop Inc., Collegeville, PA, 19426, USA
SO Journal of Medicinal Chemistry (1997), 40(13), 1941-1946
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I

AB The pyridazinodiazepine-based peptidomimetics are potent time-dependent inactivators of interleukin-1β converting enzyme (kobs/[I]) = 162,000 to 1,220,000 M-1 s-1. The corresponding aspartic acid aldehyde analogs are potent reversible inhibitors of the enzyme with inhibition consts. ranging from 1-50 nM. All of these inhibitors retain the P1 aspartic acid residue and critical hydrogen-bonding functionality, P1 and P3 NH, which are structural elements previously shown to be required for potent enzyme inhibition by peptide-based inhibitors. In addition, inhibitor I exhibits 10-15% oral bioavailability in the dog.

IT **174799-03-2P 174799-04-3P 174799-05-4P**
174799-06-5P 174799-07-6P 174799-10-1P
174799-15-6P 174799-16-7P 174799-17-8P
174799-22-5P 174799-23-6P 174799-24-7P
174799-28-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1β-converting enzyme inhibitor)

RN 174799-03-2 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-04-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-05-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 174799-06-5 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-07-6 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-10-1 CAPLUS
CN Pentanoic acid, 3-[[[9-[[4-[(carboxymethyl)thio]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-15-6 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 174799-16-7 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(4-methyl-

1-
piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 174799-17-8 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(2-methyl-1H-
imidazol-1-yl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-22-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-
(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4α(R*),7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CF3

RN 174799-23-6 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-24-7 CAPLUS
CN Butanoic acid, 3-[[[9-[[4-(carboxymethoxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-28-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:214750 CAPLUS Full-text
DN 124:290273
TI Preparation of peptide analogs as inhibitors of interleukin-1 beta converting enzyme (ICE)
IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.
PA Vertex Pharmaceuticals Incorp., USA
SO PCT Int. Appl., 374 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5847135	A	19981208	US 1995-440898	19950525
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	BR 9508051	A	19971021	BR 1995-8051	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 6420522	B1	20020716	US 1999-430822	19991029
PRAI	US 1994-261452	A	19940617		
	US 1995-405581	A	19950317		
	US 1995-440898	A	19950525		
	US 1995-465216	A3	19950605		
	WO 1995-US7617	W	19950616		

OS MARPAT 124:290273
GI



I



II

AB Novel classes of compds. are prepared, which are characterized by specific structural and physicochem. features comprising (a) a first and a second hydrogen bonding moiety, each of said moieties being capable of forming a hydrogen bond with a different backbone atom of ICE selected from the carbonyl O and the amide NH group of Arg-341 Ser-339, (b) a first and a second moderately hydrophobic moiety, said moieties each being capable of associating with a sep. binding pocket of ICE when the inhibitor is bound thereto, said binding pocket being selected form the P2, P3, P4, and P' binding pockets, and (c) an electroneg. moiety comprising ≥1 electroneg. atoms, said atoms being attached to the same atom or to adjacent atoms in the moiety and said moiety being capable of forming ≥1 hydrogen bonds or salts bridges with residues in the P1 binding pocket of ICE. These compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. Thus, etherification of Me N-tert-butoxycarbonyl-cis-4-hydroxyprolinate with phenol using Ph3P and di-Et azodicarboxylate in THF to Me N-tert-butoxycarbonyl-cis-4-phenoxyprolinate followed by deprotection with HCl in EtOAc to Me 4-phenoxyprolinate hydrochloride and condensation with Ac-Tyr-Val-OH using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBT, and diisopropylethylamine in DMF gave Me N-acetyl-L-tyrosinyl-L-valyl-(4-phenoxy)prolinate. Saponification of the latter peptide ester with LiOH in aqueous THF to N-acetyl-L-tyrosinyl-L-valyl-(phenoxy)proline followed by condensation with N-allyloxycarbonyl-4-amino-5-benzyloxy-2-oxotetrahydrofuran gave N-[N-acetyl-L-tyrosinyl-L-valyl-(4-phenoxy)prolinyl]-4-amino-5-benzyloxy-2-oxotetrahydrofuran (1:1 diastereomer mixture), which underwent hydrogenolysis over Pd(OH)2 in MeOH under H atmospheric to give the title compound (I). In a IL-1β assay with a mixed population of human peripheral blood mononuclear cells or enriched adherent mononuclear cells, I in vitro showed IC50 of 2.6 and 0.25 μM for inhibiting the processing of pre-IL-1β by ICE.

IT **175209-10-6P 175209-11-7P 175209-35-5P**
175209-36-6P 175209-41-3P 175209-44-6P
175209-48-0P 175209-61-7P 175209-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-44-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)(CA INDEX NAME)

Absolute stereochemistry.



RN 175209-48-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **175211-62-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175211-62-8 CAPLUS

CN Pentanoic acid, 5-[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:190878 CAPLUS Full-text
DN 124:261732
TI Preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as interleukin-1β converting enzyme inhibitors
IN Dolle, Roland E.; Chaturvedula, Prasad V.; Morgan, Ross Tina; Schmidt, Stanley J.
PA Sanofi Winthrop, Inc., USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533751	A1	19951214	WO 1995-US7314	19950608
	W: AU, CA, HU, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5552400	A	19960903	US 1994-255276	19940608
	US 5639745	A	19970617	US 1995-451108	19950525
	AU 9527699	A1	19960104	AU 1995-27699	19950608
	AU 705882	B2	19990603		
	EP 764167	A1	19970326	EP 1995-923013	19950608
	EP 764167	B1	20031022		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 76334	A2	19970828	HU 1996-3376	19950608
	JP 10501244	T2	19980203	JP 1995-501315	19950608
	AT 252585	E	20031115	AT 1995-923013	19950608
	EP 1391461	A1	20040225	EP 2003-18280	19950608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
PRAI	US 1994-255276	A	19940608		
	EP 1995-923013	A3	19950608		
	WO 1995-US7314	W	19950608		

OS MARPAT 124:261732
GI



I

AB ZNHY [Y = CRR1(CH2)nCO2R2; R = C:NNHCONH2, COR3, etc.; R1 = H or deuterium; R2 = OH, alkoxy, NHOH, etc.; R3 = H, pyrazolyloxymethyl, benzoyloxymethyl, etc.; Z = azabicyclllylcarbonyl, etc.; n = 1 or 2] were prepared Thus, pyridazinodiazepinecarboxylate I (R5 = PhCH2O2C, R6 = H)

was amidated and the deprotected product amidated to give I [R5 = 4-(Me2N)C6H4CO, R6 = Q]. Selected I had IC50 of <10μM against release of interleukin-1β from human monocytes in vitro.

IT **174799-03-2P 174799-04-3P 174799-05-4P**
174799-06-5P 174799-07-6P 174799-08-7P
174799-09-8P 174799-10-1P 174799-11-2P
174799-12-3P 174799-13-4P 174799-14-5P
174799-15-6P 174799-16-7P 174799-17-8P
174799-18-9P 174799-19-0P 174799-20-3P
174799-21-4P 174799-22-5P 174799-23-6P
174799-24-7P 174799-25-8P 174799-26-9P
174799-27-0P 174799-28-1P 174799-29-2P
174799-30-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as interleukin-1β converting enzyme inhibitors)

RN 174799-03-2 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-04-3 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-05-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 174799-06-5 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-07-6 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-08-7 CAPLUS
CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-09-8 CAPLUS
CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-

[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-10-1 CAPLUS
CN Pentanoic acid, 3-[[[9-[[4-[(carboxymethyl)thio]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-11-2 CAPLUS
CN Pentanoic acid, 3-[[[9-[[4-[(2-carboxyethyl)thio]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CF3

RN 174799-12-3 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-9-[[(2-methylpropoxy)carbonyl]amino]-6,10-dioxo-6H-
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-13-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-14-5 CAPLUS
CN Benzenepropanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4α(R*),7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-15-6 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 174799-16-7 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,

[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 174799-17-8 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(2-methyl-1H-
imidazol-1-yl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,
[1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-18-9 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 3-[[[9-[(1H-benzimidazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-19-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 3-[[[9-[(1H-benzotriazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-20-3 CAPLUS

CN 1H-Benzotriazole-1-carboxylic acid, 5-[[[4-[[[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, 1-ethyl ester, [4S-[4α(R*),7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OEt

RN 174799-21-4 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 5-[[[4-[[[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, 1-ethyl ester, [4S-[4α(R*),7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OEt

RN 174799-22-5 CAPLUS
CN Benzenebutanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4α(R*),7α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-24-7 CAPLUS

CN Butanoic acid, 3-[[[9-[[4-(carboxymethoxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-25-8 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-10-oxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-26-9 CAPLUS
CN Pentanoic acid, 5-[[1-(5-chloro-2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-27-0 CAPLUS
CN Pentanoic acid, 3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-28-1 CAPLUS
CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)(CA INDEX NAME)

Absolute stereochemistry.



RN 174799-29-2 CAPLUS
CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[(2-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-30-5 CAPLUS
CN Butanoic acid, 3-[[[octahydro-9-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **174799-33-8P 174799-34-9P 174799-35-0P**
174799-36-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as interleukin-1β converting enzyme inhibitors)

RN 174799-33-8 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-34-9 CAPLUS

CN Pentanoic acid, 3-[[(9-aminooctahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl)carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, 1,1-dimethylethyl ester, monohydrochloride, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-35-0 CAPLUS
CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174799-36-1 CAPLUS
CN Hexanoic acid, 6-[(aminocarbonyl)hydrazono]-3-[[[octahydro-6,10-dioxo-9-[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(3R*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L7 ANSWER 1 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	8372336
Autonom Name (AUN):	3-<(9-benzoylamino-6,10-dioxo-octahydro-pyridazino<1,2-a><1,2>diazepine-1-carbonyl)-amino>-N-methoxy-N-methyl-succinamic acid tert-butyl ester
Molec. Formula (MF):	C27 H37 N5 O8
Molecular Weight (MW):	559.62
Lawson Number (LN):	29859, 10581, 3625, 3487, 318, 289
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7107718
Tautomer ID (TAUTID):	7902041
Entry Date (DED):	2000/03/08
Update Date (DUPD):	2000/03/08



Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592; BABS-6189425

L7 ANSWER 2 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	8368830
Autonom Name (AUN):	3-<(9-benzoylamino-6,10-dioxo-octahydro-pyridazino<1,2-a><1,2>diazepine-1-carbonyl)-amino>-4-oxo-butyric acid tert-butyl ester
Molec. Formula (MF):	C25 H32 N4 O7
Molecular Weight (MW):	500.55
Lawson Number (LN):	29859, 10581, 3614, 318
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7104430
Tautomer ID (TAUTID):	7901073
Entry Date (DED):	2000/03/08
Update Date (DUPD):	2000/03/08



Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592; BABS-6189425

L7 ANSWER 3 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7791359
Molec. Formula (MF):	C34 H32 Cl F3 N6 O10 S
Molecular Weight (MW):	809.17
Lawson Number (LN):	29859, 28329, 16436, 11689, 3616, 1774
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6647679
Tautomer ID (TAUTID):	7373455
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 4 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7791282
Molec. Formula (MF):	C36 H36 Cl F3 N6 O10
Molecular Weight (MW):	805.16
Lawson Number (LN):	29859, 28329, 16436, 11187, 3616
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6648049
Tautomer ID (TAUTID):	7373231
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 5 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7791183
Molec. Formula (MF):	C35 H37 Cl F3 N7 O8
Molecular Weight (MW):	776.17
Lawson Number (LN):	29859, 28329, 16436, 16047, 3616, 2817
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6646975
Tautomer ID (TAUTID):	7372503
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 6 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7791095
Molec. Formula (MF):	C36 H42 Cl2 N6 O9
Molecular Weight (MW):	773.67
Lawson Number (LN):	29859, 28000, 16047, 10584, 3616, 2817
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6647412
Tautomer ID (TAUTID):	7373666
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 7 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7791046
Molec. Formula (MF):	C33 H32 Cl F3 N6 O9
Molecular Weight (MW):	749.10
Lawson Number (LN):	29859, 28329, 16436, 5228, 3616, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6646554
Tautomer ID (TAUTID):	7370899
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 8 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7790974
Molec. Formula (MF):	C35 H39 Cl2 N5 O10
Molecular Weight (MW):	760.63
Lawson Number (LN):	30824, 29859, 16047, 10584, 3616
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6647328
Tautomer ID (TAUTID):	7373590
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 9 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7790944
Molec. Formula (MF):	C35 H36 Cl2 N6 O9
Molecular Weight (MW):	755.61
Lawson Number (LN):	29859, 28030, 16047, 10584, 3616
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6646784
Tautomer ID (TAUTID):	7374141
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 10 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7790905
Molec. Formula (MF):	C33 H33 F3 N6 O9
Molecular Weight (MW):	714.65
Lawson Number (LN):	29859, 28329, 16435, 5228, 3616, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6645676
Tautomer ID (TAUTID):	7370682
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 11 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7790071
Molec. Formula (MF):	C31 H32 Cl2 N4 O10
Molecular Weight (MW):	691.52
Lawson Number (LN):	29859, 10584, 5228, 3616, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6644745
Tautomer ID (TAUTID):	7371873
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 12 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7787164
Molec. Formula (MF):	C23 H26 N4 O10
Molecular Weight (MW):	518.48
Lawson Number (LN):	29859, 11694, 3614, 1771
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6637771
Tautomer ID (TAUTID):	7371033
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 13 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7785794
Molec. Formula (MF):	C22 H26 N4 O8
Molecular Weight (MW):	474.47
Lawson Number (LN):	29859, 5228, 3614, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6632614
Tautomer ID (TAUTID):	7365353
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 14 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7785257
Molec. Formula (MF):	C21 H23 F N4 O7
Molecular Weight (MW):	462.43
Lawson Number (LN):	29859, 10582, 3614
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6633495
Tautomer ID (TAUTID):	7367962
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



L7 ANSWER 15 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7784055
Chemical Name (CN):	PD 194035
Molec. Formula (MF):	C21 H24 N4 O7
Molecular Weight (MW):	444.44
Lawson Number (LN):	29859, 10581, 3614
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6629728
Tautomer ID (TAUTID):	7367706
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	2000/03/07



Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592; BABS-6189425

Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592; BABS-6189425

L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2004 ACS on STN
AN 126:8707 MARPAT Full-text
TI Preparation of beta-sheet mimetics of peptides or proteins as inhibitors of biologically active peptides or proteins
IN Kahn, Michael
PA Molecumetics Ltd., USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9630035	A1	19961003	WO 1996-US4044	19960325
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215695	AA	19961003	CA 1996-2215695	19960325
	CA 2215695	C	20030916		
	CA 2215720	AA	19961003	CA 1996-2215720	19960325
	AU 9653714	A1	19961016	AU 1996-53714	19960325
	AU 712581	B2	19991111		
	EP 817642	A1	19980114	EP 1996-910547	19960325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 10508034	T2	19980804	JP 1996-529567	19960325
	JP 2000319295	A2	20001121	JP 2000-79170	19960325
	ES 2161354	T3	20011201	ES 1996-910566	19960325
	US 6020331	A	20000201	US 1998-9386	19980120
	US 6245764	B1	20010612	US 1998-9665	19980120
	US 6586426	B1	20030701	US 1999-443055	19991118
	US 6699869	B1	20040302	US 2000-561107	20000428
	US 2003191109	A1	20031009	US 2001-8770	20011025

PRAI	US 1995-410518	19950324
	US 1995-549006	19951027
	JP 1996-529594	19960325
	US 1996-624690	19960325
	US 1996-624695	19960325
	WO 1996-US4044	19960325
	US 1996-725073	19961002
	US 1998-4968	19980109
	US 1998-9386	19980120
	US 1998-9665	19980120

GI



I



II

Q=



Q1=



AB There are disclosed β-sheet mimetics [I; R1 - R3 = amino acid side chain moiety or its derivative; A = CO, (CH2)1-4, (CH2)1-2-O, (CH2)1-2-S; B = N, CH; C = CO, (CH2)1-3, O, S, O(CH2)1-2, S(CH2)1-2; Y, Z = the remainder of the mol.; or any 2 adjacent CH groups of the bicyclic ring may form a double bond] and methods relating to the same for imparting or stabilizing the β-sheet structure of a peptide, protein or mol. In one aspect, the β-sheet mimetics are covalently attached at the end or within the length of the peptide or protein. The β-sheet mimetics have utility as inhibitors of one or more of proteases, kinases, CAAX motif (Ras prenylation of the Cys within its C-terminal CAAX sequence by farnesyl transferase, wherein "A" is defined as an amino acid with a hydrophobic side chain and "X" is another amino acid), peptides binding to SH2 domains, and MHC-I and/or MHC-II (major histocompatibility complex class I and class II) presentation of peptides to T cell receptors in warm-blooded animals. Thus, azabicyclo[4.3.0]nonane derivative (II; R = Boc, R4 = OH) (preparation given) was condensed with benzothiazolylarginol derivative (H-Q.CF3CO2H; R5 = Q1, Z = CHOH) using 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride, HOBt, and (Me2CH)2NEt in THF to give arginol derivative II (R = Boc, R4 = Q, R5 = Q1 Z = CHOH), which was oxidized by Dess-Martin periodinane in CH2Cl2 to arginine derivative II (R = Boc, R4 = Q, R5 = Q1 Z = CO) and deprotected 95% aqueous CF3CO2H and thioanisole at room temperature for 20 h to give, after HPLC purification, the β-sheet mimetic II (R = H, R4 = Q, R5 = H, Z = CO). The latter compound in vitro inhibited various serine proteases such as thrombin, factor VII, factor X, factor XI, urokinase, thrombin-thrombomodulin complex, activated protein C, plasmin, tissue plasminogen activator, trypsin, and tryptase, e.g. with Ki of 8.50 + 10-11 M for thrombin.

MSTR 1



G2 = N
G7 = 80



G8 = (1-4) CH2
G12 = (1-3) 24

G15 = 7-15 2-11



G29 = 162



G31 = 157



MPL: claim 1
NTE: substitution is restricted
NTE: additional double bond formation possible
STE: 443 - D

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



G1 CN,[@1],[@2]
Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:59:35 ON 04 MAR 2004)

FILE 'REGISTRY' ENTERED AT 15:59:43 ON 04 MAR 2004
L1 STRUCTURE UPLOADED
L2 16 S L1
L3 344 S L1 FUL

FILE 'CAPLUS' ENTERED AT 16:00:46 ON 04 MAR 2004
L4 12 S L3

FILE 'BEILSTEIN' ENTERED AT 16:02:07 ON 04 MAR 2004
L5 1 S L1
L6 15 S L1 FUL
L7 15 S L6 NOT L4

FILE 'MARPAT' ENTERED AT 16:03:14 ON 04 MAR 2004
L8 1 S L1
L9 10 S L1 FUL
L10 1 S L9 NOT L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	114.71	519.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.66	-8.98

STN INTERNATIONAL LOGOFF AT 16:05:04 ON 04 MAR 2004

elected compound

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:136764 CAPLUS Full-text
DN 130:196957
TI Preparation of bicyclic peptide derivatives as interleukin-1β converting enzyme inhibitors
IN Batchelor, Mark James; Bebbington, David; Bemis, Guy W.; Fridman, Wolf Herman; Gillespie, Roger John; Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Matharu, Saroop Singh; Mullican, Michael D.; Murcko, Mark A.; Murdoch, Robert; Zelle, Robert E.
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 189 pp., Cont.-in-part of U.S. Ser. No. 575,641.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874424	A	19990223	US 1996-598332	19960208
	US 6008217	A	19991228	US 1995-575641	19951220
	US 6204261	B1	20010320	US 1996-761483	19961206
	IN 182290	A	19990306	IN 1996-CA2188	19961218
	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9610798	A	19970707	ZA 1996-10798	19961220
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9612258	A	19990713	BR 1996-12258	19961220
	CN 1229412	A	19990922	CN 1996-199828	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	JP 2003137896	A2	20030514	JP 2002-306094	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	US 6258948	B1	20010710	US 1999-400639	19990921
	US 6423840	B1	20020723	US 2001-773477	20010131
	AU 756253	B2	20030109	AU 2001-76122	20010928
	US 2003225269	A1	20031204	US 2002-58522	20020128
PRAI	US 1995-575641	A2	19951220		
	US 1996-598332	A2	19960208		
	US 1996-712878	A2	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	JP 1997-523098	A3	19961220		
	WO 1996-US20843	W	19961220		
	US 1999-400639	A3	19990921		
	US 2001-773477	A3	20010131		

OS MARPAT 130:196957

GI



I



II

AB Title compds. I [m = 1-2; R3 = CN, CHO, COCH2-T1-R11, COCH2F, C:NOR9, COAr2; R5 = COR10, CO2R9, CONR102, SO2R9, SO2NHR10, COCH2OR9, COCOR10, R9, H, COCO2R10, COCONR9R10; Y = O, H2; T1 = O, S, S(O), SO2; R9 = Ar3, (un)branched C1-6 alkyl optionally unsatd. and optionally substituted with Ar3; R10 = H, Ar3, C3-6 cycloalkyl, any group R9; R11 = Ar4, (CH2)1-3Ar4, H, COAr4; R15 = OH, OAr3, NHOH, (un)branched C1-6 alkoxy optionally unsatd. and optionally substituted with Ar3, CONH2, OR5, OH, OR9, CO2H; Ar2 = (un)substituted 2-oxazolyl, 2-benzoxazolyl, 2-thiazolyl, 2-benzothiazolyl; Ar3, Ar4 = optionally substituted, nitrogen-containing heteroarom. or heterocyclic group containing 1-3 rings] were prepared as inhibitors of interleukin-1β converting enzyme. Thus, bicyclic peptide derivative II was prepared and shown to have Ki = 13 nM in a UV-visible assay and IC50 = 11000 nM in a peripheral blood mononuclear cell (PBMC) assay.

IT **192755-30-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of bicyclic peptide derivs. as interleukin-1β converting enzyme inhibitors)

RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:502830 CAPLUS Full-text
DN 127:122000
TI Inhibitors of interleukin-1β converting enzyme
IN Batchelor, Mark J.; Bebbington, David; Bemis, Guy W.; Fridman, Wolf Herman; Gillespie, Roger J.; Golec, Julian M. C.; Gu, Yong; Lauffer, David J.; Livingston, David J.; Matharu, Saroop S.; Mullican, Michael D.; Murcko, Mark A.; Murdoch, Robert; Nyce, Philip L.; Robidoux, Andrea L. C.; et al.
PA USA
SO PCT Int. Appl., 946 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6008217	A	19991228	US 1995-575641	19951220
	US 5874424	A	19990223	US 1996-598332	19960208
	US 5985863	A	19991116	US 1996-712878	19960912
	US 6204261	B1	20010320	US 1996-761483	19961206
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9612258	A	19990713	BR 1996-12258	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	AU 756253	B2	20030109	AU 2001-76122	20010928
PRAI	US 1995-575641	A	19951220		
	US 1996-598332	A	19960208		
	US 1996-712878	A	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	WO 1996-US20843	W	19961220		

OS MARPAT 127:122000
AB Compds. R(CH2)nCH(NHR1)(CR22)mR3 [R = NC, R4CH:CH, R4ON:CH, R4CR22, etc. where R2 is independently selected from H, OH, F and R4 is (un)substituted alkyl; R1 = R5NHCHR6CONR7CHR8CO, where CHR6CONR7 is a 2-oxoazepine ring substituted by benzo, pyrido, thieno, or related rings at the 6,7-position and optionally may have O, NH, S, SO, or SO2 at the 5-position, R5 and R8 are H, cyclic group, etc.; R3 = OH, COCOCO2H, CO2H, or any bioisosteric replacement for CO2H; m = 0, 1, 2; n = 0, 1]

were prepared as inhibitors of interleukin-1β converting enzyme. Thus, [1S,9S(2RS,3S)]-9- benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-N-(2-benzyloxy-5- oxotetrahydrofuran-3-yl)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide was prepared and shown to have IC50 values of 900 and 600 nM, resp., in the peripheral blood mononuclear cell (PBMC) and whole human blood assays.

IT **192755-30-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(inhibitors of interleukin-1β converting enzyme)

RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d l1; d his; log y
L1 HAS NO ANSWERS
L1              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

     (FILE 'HOME' ENTERED AT 10:10:56 ON 04 MAR 2004)

     FILE 'REGISTRY' ENTERED AT 10:11:05 ON 04 MAR 2004
L1               STRUCTURE UPLOADED
L2            0 S L1
L3            1 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 10:11:55 ON 04 MAR 2004
L4            2 S L3

     FILE 'BEILSTEIN' ENTERED AT 10:12:27 ON 04 MAR 2004
L5            0 S L1 FUL

     FILE 'MARPAT' ENTERED AT 10:12:50 ON 04 MAR 2004
L6            0 S L1
L7            0 S L1 FUL


COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             109.42     275.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -1.39

STN INTERNATIONAL LOGOFF AT 10:13:14 ON 04 MAR 2004
```

C:\Program Files\Stnexp\Queries\10058522.str





chain nodes :
12 13 14 15 16 17 18 20 21 22 23 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 19 24 31 32 33 34 35 36 37 38 39 40
chain bonds :
1-20 2-22 5-21 11-12 12-13 12-15 13-14 14-16 14-26 16-17 16-30 17-18 18-19
22-23 23-24 23-25 26-27 27-28 27-29
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 6-7 6-8 7-11 8-9 9-10 10-11 19-36 19-40 24-31 24-35
31-32 32-33 33-34 34-35 36-37 37-38 38-39 39-40
exact/norm bonds :
1-2 1-7 1-20 2-3 2-22 3-4 4-5 5-6 5-21 6-7 6-8 7-11 8-9 9-10 10-11 12-13
12-15 13-14 16-30 17-18 18-19 22-23 23-25
exact bonds :
11-12 14-16 14-26 16-17 23-24 26-27
normalized bonds :
19-36 19-40 24-31 24-35 27-28 27-29 31-32 32-33 33-34 34-35 36-37 37-38 38-39
39-40

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
40:Atom